Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months
Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint
Trial Shows Standard-Dose Radiotherapy Safer, More Effective than Higher Doses
Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial
Cediranib Demonstates Control In Alveolar Soft Part Sarcoma
Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage
Shared Decisionmaking Called For In PSA Screening For Ages 55-69
ACCP Publishes Guidelines Recommending Low-Dose CT
Study: Routine CT Not Needed In Detecting DLBCL Remissions
Surveillance Following Surgery Sufficient in Stage I Seminoma
Fitness Reduces Risk of Death From Lung, Colorectal, Prostate Cancer in Middle-Aged Men
NCI CTEP Approved Trials For the Month of May
FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing - The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document - TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
- In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?
- AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG
